Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo

Michael C. Veronesi; Yanir Aldouby; Abraham J. Domb; Michael J. Kubek

doi:10.1016/j.brainres.2009.09.039

Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo

Michael C. Veronesi, Yanir Aldouby, Abraham J. Domb, Michael J. Kubek

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Thyrotropin-releasing hormone (TRH) is reported to have anticonvulsant effects in animal seizure models and certain intractable epileptic patients. However, its duration of action is limited by rapid tissue metabolism and the blood brain barrier. Direct nose-brain delivery of neuropeptides in sustained-release biodegradable nanoparticles (NPs) is a promising mode of therapy for enhancing CNS bioavailability. Bioactivity/neuroprotection of d,l polylactide nanoparticles containing TRH was assessed against glutamate toxicity in cultured rat fetal hippocampal neurons. Subsequently, we utilized the kindling model of temporal lobe epilepsy to determine if intranasal administration of nanoparticles containing TRH (TRH-NPs) could inhibit kindling development. Animals received daily treatments of either blank (control) or TRH-NPs for 7 days before initiation of kindling. On day 8 and each day thereafter until either fully kindled or until day 20, the animals received daily treatments before receiving a kindling stimulus 3 h later. Afterdischarge duration (ADD) was assessed via electroencephalographs recorded from electrodes in the basolateral amygdalae and behavioral seizure stereotypy was simultaneously recorded digitally. Intranasal application of TRH-NPs resulted in a significant reduction in seizure ADD as kindling progressed, while the number of stimulations required to reach stage V seizures and to become permanently kindled was significantly greater in TRH-NP-treated subjects. Additionally, delay to clonus was significantly prolonged while clonus duration was reduced indicating a less severe seizure in TRH-NP-treated subjects. Our results provide proof of principle that intranasal delivery of sustained-release TRH-NPs may be neuroprotective and can be utilized to suppress seizures and perhaps epileptogenesis.

Original language	English
Pages (from-to)	151-160
Number of pages	10
Journal	Brain Research
Volume	1303
DOIs	https://doi.org/10.1016/j.brainres.2009.09.039
State	Published - 25 Nov 2009
Externally published	Yes

Bibliographical note

Funding Information:
This work was sponsored by a grant from Citizens United for Research in Epilepsy (CURE) . The authors would like to thank Mr. Daniel Kubek, Miss Amanda Weinert, Dr. William Truitt and Ms. Amy Kostrewza for their expert technical assistance. Dr. Vincent Gattone and Ms. Caroline Miller of the Indiana University School of Medicine Electron Microscopy Center were instrumental in helping us characterize the TRH-NPs. We thank Ms. Cynthia Cally, Division of Biostatistics, Department of Medicine for statistical advice. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Keywords

Epilepsy
Intranasal
Kindling
Nanoparticles
Neuroprotection
TRH

Access to Document

10.1016/j.brainres.2009.09.039

Cite this

@article{fbeb260cfc69411db4e9b2abeaaf56b5,

title = "Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo",

abstract = "Thyrotropin-releasing hormone (TRH) is reported to have anticonvulsant effects in animal seizure models and certain intractable epileptic patients. However, its duration of action is limited by rapid tissue metabolism and the blood brain barrier. Direct nose-brain delivery of neuropeptides in sustained-release biodegradable nanoparticles (NPs) is a promising mode of therapy for enhancing CNS bioavailability. Bioactivity/neuroprotection of d,l polylactide nanoparticles containing TRH was assessed against glutamate toxicity in cultured rat fetal hippocampal neurons. Subsequently, we utilized the kindling model of temporal lobe epilepsy to determine if intranasal administration of nanoparticles containing TRH (TRH-NPs) could inhibit kindling development. Animals received daily treatments of either blank (control) or TRH-NPs for 7 days before initiation of kindling. On day 8 and each day thereafter until either fully kindled or until day 20, the animals received daily treatments before receiving a kindling stimulus 3 h later. Afterdischarge duration (ADD) was assessed via electroencephalographs recorded from electrodes in the basolateral amygdalae and behavioral seizure stereotypy was simultaneously recorded digitally. Intranasal application of TRH-NPs resulted in a significant reduction in seizure ADD as kindling progressed, while the number of stimulations required to reach stage V seizures and to become permanently kindled was significantly greater in TRH-NP-treated subjects. Additionally, delay to clonus was significantly prolonged while clonus duration was reduced indicating a less severe seizure in TRH-NP-treated subjects. Our results provide proof of principle that intranasal delivery of sustained-release TRH-NPs may be neuroprotective and can be utilized to suppress seizures and perhaps epileptogenesis.",

keywords = "Epilepsy, Intranasal, Kindling, Nanoparticles, Neuroprotection, TRH",

author = "Veronesi, {Michael C.} and Yanir Aldouby and Domb, {Abraham J.} and Kubek, {Michael J.}",

note = "Funding Information: This work was sponsored by a grant from Citizens United for Research in Epilepsy (CURE) . The authors would like to thank Mr. Daniel Kubek, Miss Amanda Weinert, Dr. William Truitt and Ms. Amy Kostrewza for their expert technical assistance. Dr. Vincent Gattone and Ms. Caroline Miller of the Indiana University School of Medicine Electron Microscopy Center were instrumental in helping us characterize the TRH-NPs. We thank Ms. Cynthia Cally, Division of Biostatistics, Department of Medicine for statistical advice. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",

year = "2009",

month = nov,

day = "25",

doi = "10.1016/j.brainres.2009.09.039",

language = "אנגלית",

volume = "1303",

pages = "151--160",

journal = "Brain Research",

issn = "0006-8993",

publisher = "Elsevier",

}

TY - JOUR

T1 - Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo

AU - Veronesi, Michael C.

AU - Aldouby, Yanir

AU - Domb, Abraham J.

AU - Kubek, Michael J.

N1 - Funding Information: This work was sponsored by a grant from Citizens United for Research in Epilepsy (CURE) . The authors would like to thank Mr. Daniel Kubek, Miss Amanda Weinert, Dr. William Truitt and Ms. Amy Kostrewza for their expert technical assistance. Dr. Vincent Gattone and Ms. Caroline Miller of the Indiana University School of Medicine Electron Microscopy Center were instrumental in helping us characterize the TRH-NPs. We thank Ms. Cynthia Cally, Division of Biostatistics, Department of Medicine for statistical advice. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

PY - 2009/11/25

Y1 - 2009/11/25

N2 - Thyrotropin-releasing hormone (TRH) is reported to have anticonvulsant effects in animal seizure models and certain intractable epileptic patients. However, its duration of action is limited by rapid tissue metabolism and the blood brain barrier. Direct nose-brain delivery of neuropeptides in sustained-release biodegradable nanoparticles (NPs) is a promising mode of therapy for enhancing CNS bioavailability. Bioactivity/neuroprotection of d,l polylactide nanoparticles containing TRH was assessed against glutamate toxicity in cultured rat fetal hippocampal neurons. Subsequently, we utilized the kindling model of temporal lobe epilepsy to determine if intranasal administration of nanoparticles containing TRH (TRH-NPs) could inhibit kindling development. Animals received daily treatments of either blank (control) or TRH-NPs for 7 days before initiation of kindling. On day 8 and each day thereafter until either fully kindled or until day 20, the animals received daily treatments before receiving a kindling stimulus 3 h later. Afterdischarge duration (ADD) was assessed via electroencephalographs recorded from electrodes in the basolateral amygdalae and behavioral seizure stereotypy was simultaneously recorded digitally. Intranasal application of TRH-NPs resulted in a significant reduction in seizure ADD as kindling progressed, while the number of stimulations required to reach stage V seizures and to become permanently kindled was significantly greater in TRH-NP-treated subjects. Additionally, delay to clonus was significantly prolonged while clonus duration was reduced indicating a less severe seizure in TRH-NP-treated subjects. Our results provide proof of principle that intranasal delivery of sustained-release TRH-NPs may be neuroprotective and can be utilized to suppress seizures and perhaps epileptogenesis.

AB - Thyrotropin-releasing hormone (TRH) is reported to have anticonvulsant effects in animal seizure models and certain intractable epileptic patients. However, its duration of action is limited by rapid tissue metabolism and the blood brain barrier. Direct nose-brain delivery of neuropeptides in sustained-release biodegradable nanoparticles (NPs) is a promising mode of therapy for enhancing CNS bioavailability. Bioactivity/neuroprotection of d,l polylactide nanoparticles containing TRH was assessed against glutamate toxicity in cultured rat fetal hippocampal neurons. Subsequently, we utilized the kindling model of temporal lobe epilepsy to determine if intranasal administration of nanoparticles containing TRH (TRH-NPs) could inhibit kindling development. Animals received daily treatments of either blank (control) or TRH-NPs for 7 days before initiation of kindling. On day 8 and each day thereafter until either fully kindled or until day 20, the animals received daily treatments before receiving a kindling stimulus 3 h later. Afterdischarge duration (ADD) was assessed via electroencephalographs recorded from electrodes in the basolateral amygdalae and behavioral seizure stereotypy was simultaneously recorded digitally. Intranasal application of TRH-NPs resulted in a significant reduction in seizure ADD as kindling progressed, while the number of stimulations required to reach stage V seizures and to become permanently kindled was significantly greater in TRH-NP-treated subjects. Additionally, delay to clonus was significantly prolonged while clonus duration was reduced indicating a less severe seizure in TRH-NP-treated subjects. Our results provide proof of principle that intranasal delivery of sustained-release TRH-NPs may be neuroprotective and can be utilized to suppress seizures and perhaps epileptogenesis.

KW - Epilepsy

KW - Intranasal

KW - Kindling

KW - Nanoparticles

KW - Neuroprotection

KW - TRH

UR - http://www.scopus.com/inward/record.url?scp=71849104412&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2009.09.039

DO - 10.1016/j.brainres.2009.09.039

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 19766611

AN - SCOPUS:71849104412

SN - 0006-8993

VL - 1303

SP - 151

EP - 160

JO - Brain Research

JF - Brain Research

ER -

Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this